Clinical trials
Phase 2 Stomach Neoplasms trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 3 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 2 |
| 2018 | 5 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 9 |
| Active, not recruiting | 6 |
| Unknown status | 6 |
| Terminated | 4 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 6 |
| Novartis Pharmaceuticals | 3 |
| Eli Lilly and Company | 2 |
| Epidemiological and Clinical Research Information Network | 2 |
| Merck Sharp & Dohme LLC | 2 |
| National Cancer Center Hospital East | 2 |
| Seagen, a wholly owned subsidiary of Pfizer | 2 |
| Astellas Pharma Global Development, Inc. | 1 |
| Bayer | 1 |
| BeiGene | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stomach Neoplasms | 40 |
| Esophageal Neoplasms | 7 |
| Endometrial Neoplasms | 4 |
| Ovarian Neoplasms | 4 |
| Biliary Tract Neoplasms | 3 |
| Breast Neoplasms | 3 |
| Colorectal Neoplasms | 3 |
| Gallbladder Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Urinary Bladder Neoplasms | 3 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.